Journal of Clinical Microbiology, November 1999, p. 3469-3474, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Eijkman-Winkler Institute for Microbiology,
Received 16 April 1999/Returned for modification 21 June
1999/Accepted 22 July 1999
Streptococcal pyrogenic exotoxin A (SPE-A) and SPE-B have been
implicated in the pathogenesis of severe group A streptococcal (GAS)
disease. We studied 31 invasive GAS strains including 18 isolates from
patients with toxic shock syndrome and 22 noninvasive strains isolated
in The Netherlands between 1994 and 1998. These strains were associated
with the different allelic variants of the gene encoding SPE-A. We
selected endemic strains with speA-positive M and T
serotypes: speA2-associated M1T1 and M22-60T12 strains, speA3-associated M3T3 strains, and
speA4-associated M6T6 strains. Since
speA1-positive isolates were not frequently encountered, we
included speA1 strains of different serotypes. The GAS
strains were compared genotypically by pulsed-field gel electrophoresis and phenotypically by the in vitro production of SPE-A and SPE-B. All
strains within one M and T type appeared to be of clonal origin. Most
strains produced SPE-A and SPE-B, but only a minority of the
speA4-positive isolates did so. Among our isolates,
speA1- and speA3-positive strains produced
significantly more SPE-A than speA2- and
speA4-carrying strains, while SPE-B production was most
pronounced among speA1- and speA2-containing
strains. There was a marked degree of variability in the amounts of
exotoxins produced in vitro by strains that shared the same genetic
profile. We conclude that the differences in the in vitro production of SPE-A and SPE-B between our selected strains with identical M and T
types were not related to either genetic heterogeneity or the clinical
course of GAS disease in the patient from whom they were isolated.
*
Corresponding author. Mailing address: Eijkman-Winkler
Institute for Microbiology, Infectious Diseases, and Inflammation, Utrecht University Hospital G04.614, P.O. Box 85500, NL-3508 GA Utrecht, The Netherlands. Phone: 31-302 507627. Fax: 31-302 541770. E-mail: e.m.mascini{at}lab.azu.nl.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|